<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444988</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#141349</org_study_id>
    <nct_id>NCT02444988</nct_id>
  </id_info>
  <brief_title>Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit</brief_title>
  <acronym>SMART-MED</acronym>
  <official_title>Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The administration of intravenous fluids is ubiquitous in the care of the critically ill.
      Commonly available isotonic crystalloid solutions contain a broad spectrum electrolyte
      compositions including a range chloride concentrations. Recent studies have associated
      solutions with supraphysiologic chloride content with hyperchloremia, metabolic acidosis and
      renal vasoconstriction, acute kidney injury and renal replacement therapy, and increased
      mortality but no large, randomized-controlled trials have been conducted. SMART-MED will be a
      large, cluster-randomized, multiple-crossover trial enrolling critically ill patients from
      the Medical ICU at Vanderbilt University from June 2015 until April 2017. The primary
      endpoint will be the incidence of Major Adverse Kidney Events in 30 days after enrollment
      (MAKE30 is the composite of death, new renal replacement, or persistent renal dysfunction at
      discharge).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SMART-MED is a large, cluster-randomized, multiple-crossover trial of 0.9% saline versus
      physiologically-balanced isotonic crystalloids (Lactated Ringers or Plasma-Lyte© A) with
      regard to the incidence of major adverse kidney events by 30 days in patients admitted to the
      medical intensive care unit. Between June 2015 and April 2017, all patients admitted to the
      medical intensive care unit at Vanderbilt University medical center who are 18 years or older
      will be enrolled. The study will occur in one-month blocks. The ICU will be randomized to an
      initial fluid group (0.9% saline or physiologically balanced crystalloids). The assigned
      fluid will be used exclusively for all patients receiving isotonic crystalloid for the
      duration of the month-long block (except in the presence of pre-specified contraindications).
      The assigned study fluid will switch at the end of each month-long block such that half of
      the months are assigned to 0.9% saline and half of the months are assigned to physiologically
      balance fluid. It is anticipated that around 5,300 patients will be enrolled from the medical
      ICU during the study period. All aspects of study design, intervention, and data collection
      will be harmonized with an independent study addressing the same question in the non-medical
      intensive care units at Vanderbilt University during a similar study period (SMART-SURG). A
      pre-specified data analysis plan will dictate the harmonized analysis of SMART-MED and
      SMART-SURG.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2015</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Kidney Event Within 30 Days</measure>
    <time_frame>30 days after enrollment censored at hospital discharge</time_frame>
    <description>The primary outcome was the proportion of patients who met one or more criteria for a major adverse kidney event within 30 days — the composite of death, new receipt of renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value) — all censored at hospital discharge or 30 days after enrollment, whichever came first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day In-hospital Mortality</measure>
    <time_frame>30 days after enrollment censored at hospital discharge</time_frame>
    <description>Death before hospital discharge, censored at 30 days after enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5381</enrollment>
  <condition>Critical Illness</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>0.9% Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiologically-balanced</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.9% Saline</intervention_name>
    <description>0.9% Saline will be used whenever an isotonic crystalloid is ordered</description>
    <arm_group_label>0.9% Saline</arm_group_label>
    <other_name>Normal Saline</other_name>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiologically-balanced isotonic crystalloid</intervention_name>
    <description>Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered</description>
    <arm_group_label>Physiologically-balanced</arm_group_label>
    <other_name>Lactated Ringers</other_name>
    <other_name>Ringer's Lactate</other_name>
    <other_name>Plasma-Lyte© A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted to the medical intensive care unit (ICU) at Vanderbilt University Medical
             Center

        Exclusion Criteria:

          -  Age&lt;18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd W Rice, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, Du B, McArthur C, Myburgh J; SAFE TRIPS Investigators. Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care. 2010;14(5):R185. doi: 10.1186/cc9293. Epub 2010 Oct 15.</citation>
    <PMID>20950434</PMID>
  </reference>
  <reference>
    <citation>Yunos NM, Kim IB, Bellomo R, Bailey M, Ho L, Story D, Gutteridge GA, Hart GK. The biochemical effects of restricting chloride-rich fluids in intensive care. Crit Care Med. 2011 Nov;39(11):2419-24. doi: 10.1097/CCM.0b013e31822571e5.</citation>
    <PMID>21705897</PMID>
  </reference>
  <reference>
    <citation>Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012 Oct 17;308(15):1566-72. doi: 10.1001/jama.2012.13356.</citation>
    <PMID>23073953</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <results_first_submitted>August 19, 2019</results_first_submitted>
  <results_first_submitted_qc>November 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2019</results_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Todd Rice</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>crystalloid</keyword>
  <keyword>acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT02444988/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>For randomization, we will generate two sequences of study group assignment ([1] saline during odd-numbered months and balanced crystalloid during even-numbered months; [2] balanced crystalloid during odd-numbered months and saline during even-numbered months).
Participants will only receive 1 of the 2 interventions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.9% Sodium Chloride (Saline)</title>
          <description>Patients in an ICU block randomized to saline will receive 0.9% sodium chloride whenever isotonic intravenous fluid administration is ordered by the treating provider.
Saline: 0.9% sodium chloride will be used whenever an isotonic crystalloid is ordered</description>
        </group>
        <group group_id="P2">
          <title>Balanced Crystalloid</title>
          <description>Patients in an ICU block randomized to balanced crystalloid will receive Plasma-Lyte A or Lactated Ringer’s whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Balanced crystalloid: Lactated Ringers or Plasma-Lyte A will be used whenever an isotonic crystalloid is ordered</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2646"/>
                <participants group_id="P2" count="2735"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2646"/>
                <participants group_id="P2" count="2735"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the 15,802 patient enrolled in the SMART trial, 7860 were assigned to saline and 7,942 were assigned to balanced crystalloids. Of these, 5,381 were admitted to the medical ICU, with 2646 assigned to saline and 2735 assigned to balanced crystalliods.</population>
      <group_list>
        <group group_id="B1">
          <title>0.9% Sodium Chloride (Saline)</title>
          <description>Patients in an ICU block randomized to saline will receive 0.9% sodium chloride whenever isotonic intravenous fluid administration is ordered by the treating provider.
Saline: 0.9% sodium chloride will be used whenever an isotonic crystalloid is ordered</description>
        </group>
        <group group_id="B2">
          <title>Balanced Crystalloid</title>
          <description>Patients in an ICU block randomized to balanced crystalloid will receive Plasma-Lyte A or Lactated Ringer’s whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Balanced crystalloid: Lactated Ringers or Plasma-Lyte A will be used whenever an isotonic crystalloid is ordered</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2646"/>
            <count group_id="B2" value="2735"/>
            <count group_id="B3" value="5381"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="44" upper_limit="69"/>
                    <measurement group_id="B2" value="56" lower_limit="44" upper_limit="69"/>
                    <measurement group_id="B3" value="56" lower_limit="44" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1251"/>
                    <measurement group_id="B2" value="1294"/>
                    <measurement group_id="B3" value="2545"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1395"/>
                    <measurement group_id="B2" value="1441"/>
                    <measurement group_id="B3" value="2836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1978"/>
                    <measurement group_id="B2" value="2032"/>
                    <measurement group_id="B3" value="4010"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="668"/>
                    <measurement group_id="B2" value="703"/>
                    <measurement group_id="B3" value="1371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Kidney Event Within 30 Days</title>
        <description>The primary outcome was the proportion of patients who met one or more criteria for a major adverse kidney event within 30 days — the composite of death, new receipt of renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value) — all censored at hospital discharge or 30 days after enrollment, whichever came first.</description>
        <time_frame>30 days after enrollment censored at hospital discharge</time_frame>
        <population>Of the 15,802 patient enrolled in the SMART trial, 5381 were admitted to the medical ICU, 2646 in the saline group and 2735 in the balanced crystalloid group.</population>
        <group_list>
          <group group_id="O1">
            <title>0.9% Sodium Chloride (Saline)</title>
            <description>Patients in an ICU block randomized to saline will receive 0.9% sodium chloride whenever isotonic intravenous fluid administration is ordered by the treating provider.
Saline: 0.9% sodium chloride will be used whenever an isotonic crystalloid is ordered</description>
          </group>
          <group group_id="O2">
            <title>Balanced Crystalloid</title>
            <description>Patients in an ICU block randomized to balanced crystalloid will receive Plasma-Lyte A or Lactated Ringer’s whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Balanced crystalloid: Lactated Ringers or Plasma-Lyte A will be used whenever an isotonic crystalloid is ordered</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Kidney Event Within 30 Days</title>
          <description>The primary outcome was the proportion of patients who met one or more criteria for a major adverse kidney event within 30 days — the composite of death, new receipt of renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value) — all censored at hospital discharge or 30 days after enrollment, whichever came first.</description>
          <population>Of the 15,802 patient enrolled in the SMART trial, 5381 were admitted to the medical ICU, 2646 in the saline group and 2735 in the balanced crystalloid group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2646"/>
                <count group_id="O2" value="2735"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="659"/>
                    <measurement group_id="O2" value="615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-day In-hospital Mortality</title>
        <description>Death before hospital discharge, censored at 30 days after enrollment</description>
        <time_frame>30 days after enrollment censored at hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.9% Sodium Chloride (Saline)</title>
            <description>Patients in an ICU block randomized to saline will receive 0.9% sodium chloride whenever isotonic intravenous fluid administration is ordered by the treating provider.
Saline: 0.9% sodium chloride will be used whenever an isotonic crystalloid is ordered</description>
          </group>
          <group group_id="O2">
            <title>Balanced Crystalloid</title>
            <description>Patients in an ICU block randomized to balanced crystalloid will receive Plasma-Lyte A or Lactated Ringer’s whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Balanced crystalloid: Lactated Ringers or Plasma-Lyte A will be used whenever an isotonic crystalloid is ordered</description>
          </group>
        </group_list>
        <measure>
          <title>30-day In-hospital Mortality</title>
          <description>Death before hospital discharge, censored at 30 days after enrollment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2646"/>
                <count group_id="O2" value="2735"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467"/>
                    <measurement group_id="O2" value="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered an intervention that does not necessarily have to have a causal relationship with this treatment. An adverse event therefore can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an intervention, whether or not the incident is considered to be related to the intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.9% Sodium Chloride (Saline)</title>
          <description>Patients in an ICU block randomized to saline will receive 0.9% sodium chloride whenever isotonic intravenous fluid administration is ordered by the treating provider.
Saline: 0.9% sodium chloride will be used whenever an isotonic crystalloid is ordered</description>
        </group>
        <group group_id="E2">
          <title>Balanced Crystalloid</title>
          <description>Patients in an ICU block randomized to balanced crystalloid will receive Plasma-Lyte A or Lactated Ringer’s whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Balanced crystalloid: Lactated Ringers or Plasma-Lyte A will be used whenever an isotonic crystalloid is ordered</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="467" subjects_at_risk="2646"/>
                <counts group_id="E2" subjects_affected="418" subjects_at_risk="2735"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2646"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2735"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2646"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2735"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew W. Semler, MD, MSc</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>(615) 322-3412</phone>
      <email>matthew.w.semler@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

